

Special Issue

New Insights in Subunit Vaccines

Message from the Guest Editors

Our Special Issue focuses on subunit vaccines. Subunit vaccines differ from inactivated whole-cell vaccines, as they contain only antigenic parts of the pathogens necessary to elicit a protective immune response. By using recombinant proteins, subunit vaccines can be manufactured in a large volume at low cost. While subunit vaccines induce immune response, a generation of long-lasting immunologic memory remains a point of concern. To address these issues, antigenic properties of potential subunits of a pathogen need examination, and an understanding of particular combinations for effective, long-lasting immune response is needed. Therefore, in this Special Issue, we invite you to submit an original research or review manuscript. Articles related to development of a safe, practical, and effective subunit-based vaccine discussing identification of target antigen, adjuvant, and carrier, manufacturing of recombinant antigen, immunological responses, and testing of candidate vaccine efficacy in animal and clinical trials fall under the scope of this issue. We look forward to publishing your exciting research.

Guest Editors

Prof. Dr. Jagannadha Sastry

1. UT Health, MD Anderson Cancer Center- Graduate School of Biomedical Sciences, Houston, TX 77030, USA
2. Department of Thoracic Head & Neck Medical Oncology and Department of Comparative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Dr. Vikas Saxena

Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD 21201, USA

Deadline for manuscript submissions

closed (30 June 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/81548

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).